{"id":"W2921593132","doi":"10.1016/j.cgh.2019.02.043","title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease","year":2019,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":false,"ca_institutions":"Saint John Regional Hospital; University of Alberta; Memorial University of Newfoundland; University of Ottawa; McGill University Health Centre; University of Manitoba; Population Health Research Institute; McMaster University; St. Paul's Hospital; Dalhousie University; Hamilton Health Sciences; Université de Sherbrooke; University of Toronto; Western University; Mount Sinai Hospital; University of Calgary","funders":"AbbVie Canada; Takeda Canada; Pfizer Canada; Amgen Canada; Allergan; Bristol-Myers Squibb Canada; Eisai; Celgene; Elan; Canadian Association of Gastroenterology; UCB; Schering-Plough; Boehringer Ingelheim; Genentech; AstraZeneca Canada; Eli Lilly and Company; Alberta Health Services; Shire; Center for Visual Science; Gilead Sciences; Takeda Pharmaceutical Company; AbbVie; Abbott Laboratories; MedImmune; Merck; Pfizer","keywords":"Medicine; Maintenance therapy; Vedolizumab; Ustekinumab; Guideline; Disease; Intensive care medicine; Azathioprine; Internal medicine; Thiopurine methyltransferase; Crohn's disease; Natalizumab; Methotrexate; Infliximab; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005678463,0.001398692,0.00240992,0.005763453,0.002578158,0.003139232,0.004998712,0.006846043,0.007992639],"category_scores_gemma":[0.02446257,0.0008084063,0.00345044,0.006693289,0.001999834,0.001307232,0.001654028,0.00902894,0.00355975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02115767,"about_ca_system_score_gemma":0.06964759,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.5701857,"about_ca_topic_score_gemma":0.73682,"domain_scores_codex":[0.9916391,0.001839045,0.001739567,0.0003206989,0.003689387,0.0007721548],"domain_scores_gemma":[0.96178,0.003412855,0.002342295,0.0003731076,0.02880062,0.003291254],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009836773,0.0001221268,0.00337719,0.001393425,0.0001110512,0.0004389726,0.0001806701,0.0008012814,0.0003858546,0.002586525,0.9075173,0.08298732],"study_design_scores_gemma":[0.0005982191,0.0001313794,0.0464041,0.01853727,0.0005334281,0.002320695,0.0006750563,0.001425856,0.0004253975,0.004920863,0.923792,0.0002357047],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.006475859,0.2518032,0.02098282,0.4458583,0.0241778,0.004119582,0.02610799,0.001466334,0.2190082],"genre_scores_gemma":[0.08744704,0.3367622,0.2204931,0.1779921,0.01519065,0.007775916,0.08331294,0.0008297284,0.07019637],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.5701857,"threshold_uncertainty_score":0.8646912,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01343052723632089,"score_gpt":0.3247795408252462,"score_spread":0.3113490135889253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}